Better outcomes for interconnected conditions: The ISN’s CKM Initiative on World Heart Day
As we observe World Heart Day, today, September 29, the ISN underscores the critical intersection of cardiovascular and kidney health through its Cardio-Kidney-Metabolic (CKM) Initiative.
The ISN encourages healthcare professionals worldwide to integrate the CKM tools into their practice. By doing so, clinicians can refine their approach to treating patients with overlapping cardiovascular, kidney, and metabolic diseases, thereby improving outcomes and quality of life.
Explore ISN CKM Initiative resources
Interactive roadmap for clinicians
At the heart of the CKM Initiative is an interactive roadmap designed to assist clinicians in managing patients with cardio-kidney-metabolic conditions. This user-friendly tool allows healthcare providers to navigate patient care based on key clinical parameters, facilitating personalized, evidence-based care.
Key toolkits developed
To support the roadmap, the ISN has developed several specialized toolkits:
RAASi Optimization Toolkit: Focuses on the effective use of renin-angiotensin-aldosterone system inhibitors, addressing challenges like hyperkalemia and acute declines in eGFR.
SGLT2i Optimization Toolkit: Provides guidance on the use of sodium-glucose cotransporter 2 inhibitors, emphasizing their role in managing cardio-kidney-metabolic conditions.
CKM resources at the ISN Academy
Watch the ISN Webinar: Current evidence and the future role of non-steroidal mineralocorticoid receptor antagonists in kidney and cardiovascular disease
Watch the ISN Webinar: Understanding the cardiovascular effects of GLP-1 Receptor Agonists and implications in patients with CKD and cardiovascular disease
Understanding the CKM Initiative
Launched in 2022, the CKM Initiative is a collaborative effort between nephrologists and cardiologists to address the complex interplay between heart, kidney, and metabolic diseases. Recognizing the shared risk factors and pathophysiological mechanisms, the initiative focuses on optimizing therapies and improving patient care through comprehensive toolkits and resources.
The Cardio-Kidney-Metabolic Initiative is supported by an unrestricted educational grant from Boehringer Ingelheim & Eli Lilly Company, and Novo Nordisk.
